Antibody-based immunotherapy of solid cancers: progress and possibilities.
Antibody-based immunotherapy of solid cancers: progress and possibilities.
复制标题
DOI：
10.2217/imt.15.57
复制
发表时间：
2015
期刊：
影响因子：
2.8
通讯作者：
Nicodemus CF
中科院分区：
文献类型：
--
作者：
Nicodemus CF
单克隆抗体仍然是新型癌症治疗的主要产品选择。抗体的特性是抗原特异性和所掺入的恒定区的函数。对癌症生物学和宿主与肿瘤相互作用的分子认识的快速进步为抗体开发定义了一系列新的靶点。检查点抑制剂的临床成功验证了免疫调节和动员作为一种治疗方法。实体癌与血液恶性肿瘤不同，因为实体瘤基质含有显着的肿瘤促进和免疫抑制成分，而这些成分在血液癌中不太明显。本综述强调了工程化单克隆抗体产品如何成为针对肿瘤和基质环境的新型更个性化癌症治疗范例的潜在基石。
Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host–tumor interaction has defined a new range of targets for antibody development. The clinical success of the checkpoint inhibitors has validated immune modulation and mobilization as a therapeutic approach. Solid cancers are distinguished from hematologic malignancies because the solid tumor stroma contains significant tumor promoting and immune dampening elements less prominent in hematologic cancer. This review highlights how engineered monoclonal antibody products are emerging as potential cornerstones of new more personalized cancer treatment paradigms that target both tumor and the stromal environment.